Skip to content
TrialScanner

NCT03628612

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

Phase 2Enrolling by invitationAUTLLead

Registry record

Lead sponsor
Autolus Limited
Conditions
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma; DLBCL; ALL, Adult and Pediatric; T Cell Lymphoma
Primary completion
Jul 2043Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT03628612 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03628612: Long-term Follow-up of... | TrialScanner